238 related articles for article (PubMed ID: 29136264)
1. Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.
Menzinger S; Kaya G; Schmidt E; Fontao L; Laffitte E
Acta Derm Venereol; 2018 Feb; 98(2):284-286. PubMed ID: 29136264
[No Abstract] [Full Text] [Related]
2. Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.
Kamiya K; Aoyama Y; Noda K; Miyake T; Yamaguchi M; Hamada T; Tokura Y; Iwatsuki K
J Dermatol Sci; 2015 Apr; 78(1):77-9. PubMed ID: 25771164
[No Abstract] [Full Text] [Related]
3. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
[No Abstract] [Full Text] [Related]
4. Immunoglobulin E and bullous pemphigoid.
Cozzani E; Gasparini G; Di Zenzo G; Parodi A
Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
[TBL] [Abstract][Full Text] [Related]
5. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.
Fania L; Didona D; Pacifico V; Mariotti F; De Luca N; Abeni D; Mazzanti C; Di Zenzo G; Didona B
J Dermatol; 2018 Sep; 45(9):1135-1140. PubMed ID: 30007013
[TBL] [Abstract][Full Text] [Related]
6. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
7. A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid.
Schauer F; Kern JS; Virtic O; Technau-Hafsi K; Meiss F; Thoma K; Athanasiou I; Sitaru C; Di Zenzo G; Izumi K; Nishie W; Shimizu H; Bruckner-Tuderman L; Kiritsi D
Br J Dermatol; 2019 Jan; 180(1):231-232. PubMed ID: 30188568
[No Abstract] [Full Text] [Related]
8. Sensitivities and utility of non-invasive serological tests in the diagnosis of bullous pemphigoid.
Yew YW; Tey HL
Int J Dermatol; 2016 Sep; 55(9):e510-1. PubMed ID: 27028937
[No Abstract] [Full Text] [Related]
9. Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE.
Salz M; Haeberle S; Hoffmann J; Enk AH; Hadaschik EN
J Dermatol Sci; 2017 Sep; 87(3):309-311. PubMed ID: 28823642
[No Abstract] [Full Text] [Related]
10. Autoantibody serum levels and intensity of pruritus in bullous pemphigoid.
Bardazzi F; Barisani A; Magnano M; Tengattini V; La Placa M; Patrizi A; Balestri R
Eur J Dermatol; 2016 Aug; 26(4):390-1. PubMed ID: 27210833
[No Abstract] [Full Text] [Related]
11. Case of atypical bullous pemphigoid with generalized pruritus and eczema as the prodrome for 10 years.
Ikeda T; Okamoto K; Furukawa F
J Dermatol; 2012 Aug; 39(8):720-1. PubMed ID: 22011062
[No Abstract] [Full Text] [Related]
12. Erythema Multiforme-Like Bullous Pemphigoid.
Imbernón-Moya A; Aguilar A; Burgos F; Gallego MÁ
Actas Dermosifiliogr; 2016 Oct; 107(8):689-91. PubMed ID: 27048923
[No Abstract] [Full Text] [Related]
13. Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium.
Gutjahr A; Heck F; Emtenani S; Hammers AK; Hundt JE; Muck P; Siegel DL; Schmidt E; Stanley JR; Zillikens D; Hammers CM
Br J Dermatol; 2019 Sep; 181(3):593-594. PubMed ID: 31124130
[No Abstract] [Full Text] [Related]
14. Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients.
Ma L; Wang M; Wang X; Chen X; Zhu X
J Dermatol Sci; 2015 Apr; 78(1):76-7. PubMed ID: 25797173
[No Abstract] [Full Text] [Related]
15. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
[TBL] [Abstract][Full Text] [Related]
16. Serological investigation of bullous scabies and review of the published work.
Kokubu H; Takahashi T; Tateishi C; Tsuruta D; Hashimoto T; Tanaka T; Fujimoto N
J Dermatol; 2019 Sep; 46(9):e324-e325. PubMed ID: 30969443
[No Abstract] [Full Text] [Related]
17. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
Ujiie H
J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
[TBL] [Abstract][Full Text] [Related]
18. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.
Fairley JA; Baum CL; Brandt DS; Messingham KA
J Allergy Clin Immunol; 2009 Mar; 123(3):704-5. PubMed ID: 19152970
[No Abstract] [Full Text] [Related]
19. Anti-desmogleins autoantibodies detected by ELISA and blotting in bullous pemphigoid: what do they mean?
Julio T; Vernal S; Turatti A; Roselino AM
Int J Dermatol; 2018 Jan; 57(1):124-127. PubMed ID: 29152717
[No Abstract] [Full Text] [Related]
20. The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies.
Kasprick A; Holtsche MM; Rose EL; Hussain S; Schmidt E; Petersen F; Panicker S; Ludwig RJ
J Invest Dermatol; 2018 Feb; 138(2):458-461. PubMed ID: 28899686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
